OK-101 Eye Drops for Neuropathic Corneal Pain

OK-101 Eye Drops for Neuropathic Corneal Pain
77%49%21%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 30.0%Apr 27 • YES 45.9%Apr 28 • YES 46.2%Apr 29 • YES 30.0%Apr 30 • YES 31.9%May 1 • YES 35.1%May 2 • YES 40.2%May 3 • YES 43.1%May 4 • YES 46.4%May 5 • YES 49.8%May 6 • YES 49.8%May 7 • YES 60.7%May 12 • YES 67.5%May 13 • YES 68.1%
Okyo Pharma Ltd ($OKYO)
No stock closeNo stock close$1.73$1.60$1.47Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • OKYO $1.58Apr 28 • OKYO $1.58Apr 29 • OKYO $1.52Apr 30 • OKYO $1.56May 1 • OKYO $1.66May 4 • OKYO $1.68May 5 • OKYO $1.60May 6 • OKYO $1.68May 7 • OKYO $1.62May 8 • OKYO $1.63May 11 • OKYO $1.65May 12 • OKYO $1.62May 13 • OKYO $1.62

Will this trial show a positive result on Assess ocular pain using 0-10 visual analog scale (VAS)?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
4/30/25
Study Completion
7/1/25
Sponsor
Okyo Pharma Ltd
Ticker
$OKYO
Type
Phase 2a
Trial Status
Terminated
Trial Size
18
NCT
NCT06637527
Trial Description
This terminated Phase 2a study tested OK-101 eye drops in adults with neuropathic corneal pain, measuring ocular pain on a 0–10 scale at 16 weeks.